Management of Elevated White Blood Cell Count

Initial Assessment and Risk Stratification

• The American Society of Hematology recommends that the first priority is determining whether the leukocytosis represents a benign reactive process versus a hematologic malignancy, and whether immediate intervention is needed, with infections, inflammatory conditions, medications, smoking, obesity, physical/emotional stress, and asplenia being the most frequent causes of benign leukocytosis 1

Emergency Management of Hyperleukocytosis

• The National Comprehensive Cancer Network recommends aggressive hydration as the cornerstone of initial management for hyperleukocytosis, with intravenous fluids started at 2.5-3 liters/m²/day immediately, and titrated based on fluid balance, clinical status, and WBC count 2, 1
• The National Comprehensive Cancer Network recommends cytoreduction with hydroxyurea, initiated at 50-60 mg/kg/day, to achieve 50% WBC reduction within 1-2 weeks, and started concurrently with hydration once hyperleukocytosis is confirmed 3, 2, 1
• The European Hematology Association recommends considering leukapheresis for symptomatic leukostasis, which can achieve 30-80% WBC reduction within hours, but avoiding it in acute promyelocytic leukemia due to risk of fatal hemorrhage 4, 1

Definitive Treatment Based on Underlying Diagnosis

• The National Comprehensive Cancer Network recommends standard induction chemotherapy for acute myeloid leukemia, consisting of cytarabine and an anthracycline, with growth factors not routinely recommended post-induction 4, 3, 1
• The American Society of Hematology recommends special management considerations for acute promyelocytic leukemia, including aggressive platelet transfusion support, fibrinogen replacement, and monitoring for APL differentiation syndrome 3
• The European Hematology Association recommends starting hydroxyurea for children with hyperleukocytosis at diagnosis, and beginning tyrosine kinase inhibitor therapy once BCR::ABL1 fusion is confirmed 2, 1
• The International Waldenström's Macroglobulinemia Foundation recommends plasmapheresis immediately for symptomatic hyperviscosity, and avoiding rituximab monotherapy in patients with high IgM due to flare risk 5

Common Pitfalls to Avoid

• The National Comprehensive Cancer Network recommends never delaying hydration and cytoreduction while waiting for definitive diagnosis in hyperleukocytosis, and avoiding leukapheresis in APL without extreme caution due to hemorrhage risk 1, 3